Burning Rock (BNR) has recently announced a collaboration with Bayer (BAYRY) to develop next-generation sequencing, or NGS-based companion diagnostic assays, or CDx, aiming to provide diagnostic methods, to enable treatment choice for patients with cancer in China, while driving innovation and development in cancer therapy. This collaboration will focus on the development of companion diagnostic products in China, jointly developing NGS-based CDx for Bayer’s growing portfolio of precision cancer therapies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNR:
- Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
- Burning Rock Biotech Aims for 2024 Breakeven
- Burning Rock Biotech Announces Q1 Results Date
- Burning Rock Schedules First Quarter of 2024 Earnings Release on May 29, 2024
- Burning Rock Biotech Ltd (ADR) trading halted, news pending